At TAPI, scientific excellence is demonstrated through the way we design, optimize, and scale complex chemical processes. A newly published peer-reviewed paper from our R&D colleagues in Czechia, featured in Organic Process Research & Development (OPRD), highlights this approach through the development of a scalable synthetic route toward a key intermediate in Cantharidin.
The publication showcases TAPI’s capabilities in advanced chemistry, crystallization development, and data-driven process optimization, applying Design of Experiments (DoE) and Quality-by-Design (QbD) principles to deliver a robust and industrially viable process.
Why Cantharidin—and why now?
Cantharidin is a highly potent natural terpenoid historically sourced from blister beetles. In recent years, interest in reliable synthetic manufacturing has grown—especially as pharmaceutical demand increases and supply chains seek reproducible quality, controlled impurities, and scalable production routes.
In 2023, U.S. Food and Drug Administration announced approval of YCANTH (cantharidin) as the first treatment indicated for molluscum contagiosum, further reinforcing the need for robust manufacturing approaches to meet rising demand.
What the paper demonstrates
The team reports a lithium iodide (LiI)–mediated Diels–Alder cycloaddition that achieves:
- High conversion efficiency under practical conditions
- Excellent stereoselectivity (exo-selectivity)—reported as the highest to date in the paper’s context
- Operational robustness, with conditions described as water- and air-tolerant
- A process that was successfully scaled to the hundred-gram level using straightforward reactions and work-ups
DoE-driven optimization to support QbD
Rather than relying on one-factor-at-a-time optimization, the work applies a structured DoE approach to evaluate key parameters and interactions—supporting a QbD development mindset:
- Identifying which factors most strongly influence conversion and process operability
- Balancing conversion and selectivity with practical considerations like agitation parametersEnabling greater confidence in robustness and reproducibility when moving toward larger scale
This is a strong example of how TAPI R&D brings data-driven process understanding into early development—setting the stage for smoother tech transfer and scale-up.
A standout: crystallization-based isolation (no chromatography)
One of the most practical highlights is the crystallization-based isolation protocol reported for the first time for this intermediate:
- Enables isolation of a pure exo-isomer
- Removes byproducts and residual salt without relying on chromatography
- Provides a scalable approach aligned with industrial manufacturing expectations
This crystallization strategy is a strong demonstration of our capabilities in solid-state understanding, isolation development, and impurity control—all essential for building scalable, manufacturable routes.
Built with sustainability and cost efficiency in mind
Beyond performance, the process development choices reflect modern process expectations:
- Avoiding less desirable systems that require large excesses of certain salts
- Using conditions designed for industrial operability
- Introducing the possibility of recovering lithium iodide to improve overall cost efficiency
This work reflects TAPI’s ability to translate deep scientific understanding into scalable, reproducible, and manufacturing-ready processes, supported by strong solid-state and crystallization expertise.
Read the full article in Organic Process Research & Development to explore the complete methodology, data, and process insights.
Scalable Synthesis of Cantharidin: Lithium Iodide as a Stereoselective and Efficient Catalyst in the Diels–Alder Reaction toward a Key Intermediate | Organic Process Research & Development
TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of any exclusive rights(such as patents and/or supplementary protection certificates or extensions) in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.
